MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-06-2026
STERIS plc Operating Income 2011-2026 | STE
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income STERIS plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 867 M | 836 M | 791 M | 478 M | 548 M | 537 M | 411 M | 400 M | 226 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 867 M | 226 M | 566 M |
Quarterly Operating Income STERIS plc
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 273 M | 266 M | 246 M | - | 245 M | 220 M | 186 M | - | 226 M | 192 M | 198 M | - | 191 M | -306 M | 158 M | - | 203 M | 334 M | 131 M | - | 147 M | 147 M | 141 M | 114 M | 142 M | 142 M | 127 M | 110 M | 69.6 M | 107 M | 94.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 334 M | -306 M | 158 M |
Operating Income of other stocks in the Medical instruments industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AtriCure
ATRC
|
-9.45 M | $ 29.85 | 1.05 % | $ 1.43 B |  USA |
 |
AngioDynamics
ANGO
|
-40 M | $ 10.6 | -1.03 % | $ 433 M | USA |
 |
Atrion Corporation
ATRI
|
22.6 K | - | - | $ 810 M | USA |
 |
Harvard Bioscience
HBIO
|
1.89 M | $ 0.47 | -4.15 % | $ 19.9 M | USA |
 |
Alcon
ALC
|
580 M | $ 77.32 | -1.5 % | $ 40.4 B |  Schweiz |
 |
ICU Medical
ICUI
|
42.8 M | $ 125.85 | -2.28 % | $ 3.1 B | USA |
 |
InfuSystem Holdings
INFU
|
1.65 M | $ 9.31 | -0.85 % | $ 192 M | USA |
 |
iRhythm Technologies
IRTC
|
-57.4 M | $ 113.0 | -1.46 % | $ 3.62 B | USA |
 |
Intuitive Surgical
ISRG
|
2.95 B | $ 472.16 | -1.48 % | $ 169 B | USA |
 |
The Cooper Companies
COO
|
683 M | $ 69.92 | -2.24 % | $ 13.9 B | USA |
 |
Glaukos Corporation
GKOS
|
-129 M | $ 97.02 | -0.79 % | $ 4.7 B | USA |
 |
Becton, Dickinson and Company
BDX
|
2.58 B | $ 159.36 | -0.17 % | $ 45.8 B | USA |
 |
Haemonetics Corporation
HAE
|
222 M | $ 59.92 | 0.72 % | $ 3.02 B | USA |
 |
electroCore
ECOR
|
-19.3 M | $ 6.14 | -3.0 % | $ 33.9 K | USA |
 |
Masimo Corporation
MASI
|
-267 M | $ 175.49 | -0.01 % | $ 9.35 B | USA |
 |
Isoray
ISR
|
-90.9 M | - | 0.03 % | $ 108 M | USA |
 |
Predictive Oncology
POAI
|
-10.9 M | - | - | $ 31.1 M | USA |
 |
Ekso Bionics Holdings
EKSO
|
-13.3 M | $ 11.56 | -2.12 % | $ 28 M | USA |
 |
Repro Med Systems
KRMD
|
-2.97 M | $ 4.28 | -0.7 % | $ 198 M | USA |
 |
Baxter International
BAX
|
-308 M | $ 17.4 | -3.36 % | $ 8.93 B | USA |
 |
BioLife Solutions
BLFS
|
-7.13 M | $ 18.36 | 1.16 % | $ 846 M | USA |
 |
Nephros
NEPH
|
-1.59 M | $ 3.5 | -7.89 % | $ 36.4 M | USA |
 |
ResMed
RMD
|
1 B | $ 230.84 | -0.68 % | $ 33.7 B | USA |
 |
Retractable Technologies
RVP
|
-21.1 M | $ 0.71 | 2.62 % | $ 21.3 M | USA |
 |
NeuroMetrix
NURO
|
-8.78 M | - | 5.05 % | $ 9.02 M | USA |
 |
Merit Medical Systems
MMSI
|
185 M | $ 69.95 | 2.61 % | $ 4.14 B | USA |
 |
Envista Holdings Corporation
NVST
|
216 M | $ 24.61 | -3.26 % | $ 4.13 B | USA |
 |
STAAR Surgical Company
STAA
|
-91.7 M | $ 18.84 | 2.45 % | $ 934 M | USA |
 |
Stereotaxis
STXS
|
-22.1 M | $ 1.89 | 0.27 % | $ 172 M | USA |
 |
Teleflex Incorporated
TFX
|
13.9 M | $ 107.32 | -0.87 % | $ 4.79 B | USA |
 |
OraSure Technologies
OSUR
|
-72 M | $ 2.97 | -3.88 % | $ 218 M | USA |
 |
LeMaitre Vascular
LMAT
|
67.9 M | $ 108.06 | 1.43 % | $ 2.45 B | USA |
 |
Utah Medical Products
UTMD
|
16.8 M | $ 63.28 | 1.02 % | $ 230 M | USA |
 |
Pro-Dex
PDEX
|
10.7 M | $ 48.46 | 3.5 % | $ 159 M | USA |
 |
Microbot Medical
MBOT
|
-9.86 M | $ 2.69 | -1.47 % | $ 27.4 M |  Israel |
 |
West Pharmaceutical Services
WST
|
585 M | $ 235.46 | 1.89 % | $ 17 B | USA |
 |
Repligen Corporation
RGEN
|
47.7 M | $ 114.2 | 0.39 % | $ 6.36 M | USA |
 |
DENTSPLY SIRONA
XRAY
|
-422 M | $ 11.54 | -2.2 % | $ 2.3 B | USA |
 |
Pulse Biosciences
PLSE
|
-76.9 M | $ 21.57 | 1.27 % | $ 1.45 B | USA |
 |
Milestone Scientific
MLSS
|
-6.76 M | $ 0.28 | -3.75 % | $ 22.3 M | USA |